Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 7Completed 7Withdrawn 2Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1Glioma 1Glioblastoma 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × pamiparib × Clear all
NCT03749187 2026-03-13

PNOC017

University of California, San Francisco

Phase 1 Active not recruiting
78 enrolled
CNS

Glioblastoma, Glioma

NCT05652283 2024-11-27

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Anhui Provincial Cancer Hospital

Phase 2 Active not recruiting
37 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡